E-resources
Peer reviewed
Open access
-
Winkler, Noni Ella; Koirala, Archana; Kaur, Guddu; Prasad, Shayal; Hirani, Rena; Baker, Jannah; Hoad, Veronica; Gosbell, Iain B; Irving, David O; Hueston, Linda; O'Sullivan, Matthew VN; Kok, Jen; Dwyer, Dominic E; Macartney, Kristine; Lambert, Stephen; Williamson, Deborah; Baker, Jannah; Snelling, Tom; Glasgow, Keira; Hope, Kirsty; Luscombe, Chloe; Notaras, Adriana; Baldwin, Zoe; Case, Jennifer; Thomson, Tilda; Marsland, Madeleine; O’Brien, Helen; Deborah Friedman, N; Carroll, Heidi; Holland, Candice; Kitchener, Scott; Ratsch, Angela; Chor, Josette; Sykes, Alice; Khandaker, Gulam; Smoll, Nicolas; Walker, Jacina; Flynn, Liam; Krause, Vicki; Williams, Aleena; Hinchcliff, Alexandra; Nelson, Jane; Currie, Bart; Flood, Louise; Beazley, Rebecca; Spurrier, Nicola; Hayward, Carmen; Worley, Paul
BMJ open, 02/2024, Volume: 14, Issue: 2Journal Article
IntroductionJapanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors.MethodSamples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses.AnalysisTwo analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model.EthicsNational Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were planned to be sought in each jurisdiction, as per local ethics processes. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC.DisseminationFindings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.